Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Eli Lilly & Co.’s shares fell the most intraday since October after CVS Health Corp. announced a plan to drop its blockbuster ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

CEO Dave Ricks on Thursday said the drugmaker can help “respond” to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The Trump administration has ...

Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company ...

Get ready to be swept away by the latest bengali song Dakat Poreche beautifully sung by Iman Chakraborty. This captivating ...